CRISPR Therapeutics AG (CRSP) Share-based Compensation (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Share-based Compensation data on file, last reported at $72.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 257.71% year-over-year to $72.3 million; the trailing twelve-month figure through Mar 2026 stood at $72.3 million (down 17.25% YoY), and the FY2025 full-year result was $72.5 million, down 16.25% from the prior year.
• Share-based Compensation climbed to $72.3 million in Q1 2026, from $18.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $72.3 million in Q1 2026 to a low of $17.6 million in Q2 2025.
• A 5-year average of $26.7 million and a median of $21.8 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation fell 25.62% in 2025 and soared 257.71% in 2026, its largest moves.
• Tracing CRSP's Share-based Compensation over 5 years: stood at $22.8 million in 2022, then fell by 19.35% to $18.4 million in 2023, then gained by 19.33% to $21.9 million in 2024, then decreased by 17.63% to $18.1 million in 2025, then surged by 299.96% to $72.3 million in 2026.
• Business Quant data shows CRSP's Share-based Compensation at $72.3 million in Q1 2026, $18.1 million in Q4 2025, and $60.1 million in Q3 2025.